KLRA (Kailera Therapeutics) EV-to-FCF: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kailera Therapeutics's Enterprise Value is $1,735.37 Mil. Kailera Therapeutics does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Kailera Therapeutics's EV-to-FCF at this moment.

The historical rank and industry rank for Kailera Therapeutics's EV-to-FCF or its related term are showing as below:

KLRA' s EV-to-FCF Range Over the Past 10 Years
Min: -14.37   Med: 0   Max: 0
Current: -14.19
KLRA's EV-to-FCF is ranked worse than
100% of 349 companies
in the Biotechnology industry
Industry Median: 14.06 vs KLRA: -14.19

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-03), Kailera Therapeutics's stock price is $17.32. Kailera Therapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Kailera Therapeutics's PE Ratio (TTM) at this moment.

Kailera Therapeutics  (NAS:KLRA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Kailera Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=17.32/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Kailera Therapeutics EV-to-FCF Related Terms

Kailera Therapeutics EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics EV-to-FCF Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-FCF
0.00 0.00

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-FCF 0.00 0.00

KLRA vs VCEL, NUVB, IOVA: EV-to-FCF Comparison

For the Biotechnology subindustry, Kailera Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kailera Therapeutics EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kailera Therapeutics's EV-to-FCF falls into.


KLRA
11GF Score
Kailera Therapeutics Inc KLRA
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics EV-to-FCF Calculation

Kailera Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1735.372/
=

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price